MRI results from a phase III, randomised, doubleblind, placebo-controlled, multi-centre trial (REFLEX) of two dosing frequencies of subcutaneous interferon β-1a in patients with a first demyelinating event suggestive of multiple sclerosis: O283


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles